<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799014</url>
  </required_header>
  <id_info>
    <org_study_id>2022-NHLHCRF-LX-01-0201-01</org_study_id>
    <nct_id>NCT05799014</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Electromagnetic Navigation Real-time Guided Percutaneous Lung Biopsy</brief_title>
  <official_title>The Effectiveness and Safety of Percutaneous Lung Biopsy Guided by Electromagnetic Navigation Real-time Positioning Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China-Japan Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate the diagnostic efficacy and safety of&#xD;
      percutaneous lung biopsy guided by electromagnetic navigation real-time positioning&#xD;
      technology in peripheral lung lesions. The main question it aims to answer are: the&#xD;
      effectiveness and safety of percutaneous lung biopsy guided by electromagnetic navigation&#xD;
      real-time positioning technology.&#xD;
&#xD;
      Participants will undergo CT-guided percutaneous lung biopsy or percutaneous lung biopsy&#xD;
      guided by electromagnetic navigation real-time positioning technology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology for diagnosis of pleural effusion.</measure>
    <time_frame>7 days after the lung biopsy</time_frame>
    <description>The diagnosis would be confirmed according to the pathological results or multidisciplinary discussion results (if interstitial lung disease is suspected, the multidisciplinary discussion results shall be recorded).&#xD;
The diagnostic efficacy of percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology will be compared with that of CT-guided percutaneous lung biopsy for diagnosis of pleural effusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>during the operation of lung biopsy</time_frame>
    <description>Timer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peripheral Lung Lesions</condition>
  <arm_group>
    <arm_group_label>Traditional CT-guided percutaneous lung biopsy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CT-guided percutaneous lung biopsy</intervention_name>
    <description>The participants would undergo CT-guided percutaneous lung biopsy.</description>
    <arm_group_label>Traditional CT-guided percutaneous lung biopsy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology</intervention_name>
    <description>The participants would undergo percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.</description>
    <arm_group_label>Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years old&#xD;
&#xD;
          -  Imaging examination showed peripheral lung lesions&#xD;
&#xD;
          -  Selected patients need to complete routine preoperative examinations such as blood&#xD;
             routine examination, coagulation function, electrocardiogram, chest CT, etc&#xD;
&#xD;
          -  There is no contraindication for puncture biopsy&#xD;
&#xD;
          -  Good compliance, able to cooperate with research and observation&#xD;
&#xD;
          -  Fully informed of the purpose and method of the study, agreed to participate in the&#xD;
             study, and signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiopulmonary insufficiency, extreme weakness and intolerance of patients&#xD;
&#xD;
          -  The patient is allergic to lidocaine and midazolam&#xD;
&#xD;
          -  The site to be biopsied has a high risk of bleeding such as bronchial artery&#xD;
             penetration or suspected lung metastasis of renal cancer&#xD;
&#xD;
          -  Unstable angina pectoris, congestive heart failure, severe bronchial asthma&#xD;
&#xD;
          -  The patient did not agree to participate in the study&#xD;
&#xD;
          -  Participation in other studies within three months without withdrawal or termination&#xD;
             will affect the observation of this study&#xD;
&#xD;
          -  The researcher believes that there is any person who is not suitable for the selection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mingming Deng, MD</last_name>
    <phone>86 18801336854</phone>
    <email>isdeng1017@163.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China-Japan Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Gang Hou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

